FTI
SAGE

Fiduciary Trust International’s Sage Therapeutics SAGE Stock Holding History

Fiduciary Trust International’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5
Closed – – 490
2018
Q4 		$0 Buy
+5
New +$572 ﹤0.01% 676

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fiduciary Trust International's SAGE Position: Q1 2019 in Review

Fiduciary Trust International sold out of Sage Therapeutics (SAGE) in Q1 2019, closing a stake of 5 shares.

Fiduciary Trust International first reported a position in SAGE in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 267 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

  • Fiduciary Trust International reported no remaining Sage Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Fiduciary Trust International sold 5 Sage Therapeutics shares in Q1 2019.
  • Fiduciary Trust International first reported a position in Sage Therapeutics in Q4 2018 and held it in 1 quarter.
  • Fiduciary Trust International's Sage Therapeutics position peaked at $0 in Q4 2018.
  • 267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on Fiduciary Trust International's 13F filing for Q1 2019, filed 7 May 2019.